The news of a potential COVID-19 vaccine was welcome news this week, but ensuing announcements made it clear there's still a long way to go in the fight against the novel coronavirus. Carl Zimmer, a science writer for the New York Times who has covered the competing trials for a COVID-19 vaccine, told the paper's podcast The Daily that he at first thought the 90 per cent figure might be a typo. With Pfizer hoping to have its first vaccines available in January, "it shatters all records for vaccine development." WATCH: See how world markets reacted to the Pfizer announcement:Prospect of Pfizer vaccine boosts stock market 1:31 Stock markets surged Monday partly because of news surrounding the Pfizer vaccine. The Pfizer-BioNTech vaccine will also require quite the effort, as it's introduced in two doses, at least a week apart.

Source: CBC News November 14, 2020 09:22 UTC